Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner-Lambert Company
Thomas Michael Andrew Bocan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company, Thomas Michael Andrew BocanfiledCriticalWarner-Lambert Company
Priority claimed from PCT/US1996/015854external-prioritypatent/WO1997016184A1/en
Publication of CA2233558A1publicationCriticalpatent/CA2233558A1/en
Application grantedgrantedCritical
Publication of CA2233558CpublicationCriticalpatent/CA2233558C/en
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
The present invention is a combination of an ACAT inhibitor for example, sulfamic acid, [[2,4,6; tris(1-methylethyl)phenyl]acetyl]-, 2,6-bis(1-methylethyl)phenyl ester, and an HMG-CoA-reductase inhibitor, for example, atorvastatin, effective for lipid regulation. The combination of agents results in a greater reduction in plasma VLDL and LDL cholesterol and increases HDL cholesterol than either alone resulting in a less atherogenic lipoprotein profile. The combination is useful in the treatment of patients with or at risk of developing ischemic syndromes in order to restore endogenous vascular endothelium-dependent activities.
CA002233558A1995-11-021996-10-02Method and pharmaceutical composition for regulating lipid concentration
Expired - Fee RelatedCA2233558C
(en)
Regulating lipid concentration in mammals by administering an acyl-CoA cholesterol O-acyltransferase (ACAT) inhibitor and an HMG-CoA reductase inhibitor